Updated on 2024/04/08

写真a

 
KOYAMA Junji
 
Organization
Nagoya University Hospital Respiratory Medicine Assistant professor of hospital
Title
Assistant professor of hospital

Degree 1

  1. 学士(医学) ( 2010.3   名古屋大学 ) 

Research Interests 1

  1. 肺癌

Research Areas 2

  1. Life Science / Respiratory medicine

  2. Life Science / Tumor diagnostics and therapeutics

Current Research Project and SDGs 2

  1. 胸部悪性腫瘍に対する薬物療法

  2. 胸部悪性腫瘍治療における機械学習の活用

Research History 1

  1. Nagoya University Hospital   Department of Respiratory Medicine   Assistant Professor

    2023.4

      More details

    Country:Japan

Education 2

  1. Nagoya University   Graduate School of Medicine

    2019.4 - 2023.3

      More details

    Country: Japan

  2. Nagoya University   School of Medicine   Department of Medicine

    2004.4 - 2010.3

      More details

    Country: Japan

Professional Memberships 6

  1. 日本内科学会

  2. 日本呼吸器学会

  3. 日本呼吸器内視鏡学会

  4. 日本肺癌学会

  5. 日本臨床腫瘍学会

  6. 日本メディカルAI学会

▼display all

Awards 2

  1. The 26th Congress of the Asian Pacific Society of Respirology, Assembly Education Award

    2022.11  

  2. 第4回日本メディカルAI学会学術集会、優秀一般演題賞

    2022.6  

 

Papers 27

  1. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. Reviewed International journal

    Reiko Matsuzawa, Masahiro Morise, Kentaro Ito, Osamu Hataji, Kosuke Takahashi, Junji Koyama, Yachiyo Kuwatsuka, Yasuhiro Goto, Kazuyoshi Imaizumi, Hidetoshi Itani, Teppei Yamaguchi, Yoshitaka Zenke, Masahide Oki, Makoto Ishii

    EClinicalMedicine   Vol. 66   page: 102303 - 102303   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Immune checkpoint inhibitors (ICI) plus platinum-based chemotherapy has been recognized as a standard first-line therapy in non-small cell lung cancer (NSCLC); however, no prospective clinical trials of docetaxel (DTX) plus ramucirumab (RAM) following first-line ICI plus platinum-based chemotherapy has been reported. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients with NSCLC from eight centres in Japan. Patients with metastatic NSCLC with disease progression after platinum-based chemotherapy plus ICI were eligible for the study. Patients were intravenously treated with 60 mg/m2 of DTX and 10 mg/kg of RAM on day 1 with a strong recommendation of pegfilgrastim administration on day 2 every 3 weeks. The primary end point was objective response rate (ORR) in efficacy analysis population. Safety was assessed in all patients treated at least one dose. The ORR of the null and alternative hypotheses were 10% and 30%, with α error of 0.1 and β error of 0.1. This trial is registered with the Japan Registry for Clinical Trials, jCRTs041190077. FINDINGS: Between 16 January, 2020, and 24 August, 2021, 33 patients (median age 66 [range 42-79] years) were enrolled. Thirteen patients (41%) had Eastern Cooperative Oncology Group performance status of 1. Twenty-five patients (78%) had an interval of <60 days after the last administration of ICI. In the efficacy analysis population (n = 32), the primary endpoint was met as 11 patients achieved partial response (PR), with ORR of 34.4% (80% CI, 23.1-47.2). Grade ≥3 anaemia and febrile neutropenia were observed in 2 (6%) and 3 (9%) patients, respectively. No treatment-related deaths and no new safety signals were observed. INTERPRETATION: DTX plus RAM demonstrated encouraging antitumor activity with a manageable safety profile in patients who have progressed on front-line ICIs plus platinum-based chemotherapy. The results of this trial can be a helpful reference in conducting further phase III trials of new second-line treatment options. FUNDING: Eli Lilly Japan K.K.

    DOI: 10.1016/j.eclinm.2023.102303

    Web of Science

    Scopus

    PubMed

  2. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer. Reviewed International journal

    Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, Ryota Saito, Junji Koyama, Hiroaki Sakamoto, Tomoaki Sonoda, Yuko Tsuchiya-Kawano, Tomohiro Oba, Keita Kudo, Hiroshi Gyotoku, Katsumi Nakatomi, Ryo Ariyasu

    Cancer immunology, immunotherapy : CII   Vol. 72 ( 11 ) page: 3765 - 3772   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases. METHODS: This descriptive study aims to investigate the effects of second-line immunosuppressants on corticosteroid-refractory irAEs in patients with lung cancer. We analyzed the effects of second-line immunosuppressants on underlying lung cancer and associated adverse effects. RESULTS: Our study included 4589 patients who had received immune checkpoint inhibitor treatment, with 73 patients (1.6%) developing irAEs requiring second-line immunosuppressants. The most commonly observed irAE was pneumonitis (26 patients), followed by hepatobiliary disorders (15 patients) and enteritis (14 patients). We found a confirmed response rate of 42.3% for pneumonitis, which was lower than the response rates of 86.7% for hepatobiliary disorders and 92.9% for enteritis. The time from the start of corticosteroid therapy to the addition of a second-line immunosuppressant correlated significantly with the resolution of irAE to Grade 1 (correlation coefficients of r = 0.701, p < 0.005). The median progression-free survival and duration of response of underlying lung cancer from second-line immunosuppressant administration were 2.1 and 3.0 months, respectively. Of the patients with irAE, 27.4% developed infections and 5.5% might die due to infection. CONCLUSION: Second-line immunosuppressant response was confirmed in 72.2% of irAEs in patients with lung cancer, with lower response rates observed in irAE pneumonitis compared to other irAEs.

    DOI: 10.1007/s00262-023-03528-x

    Web of Science

    Scopus

    PubMed

  3. Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies. Reviewed International journal

    Ichidai Tanaka, Junji Koyama, Hideyuki Itoigawa, Shunsaku Hayai, Masahiro Morise

    Frontiers in oncology   Vol. 13   page: 1249237 - 1249237   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Currently, immune checkpoint inhibitors (ICIs) are widely considered the standard initial treatment for advanced non-small cell lung cancer (NSCLC) when there are no targetable driver oncogenic alternations. NSCLC tumors that have two alterations in tumor suppressor genes, such as liver kinase B1 (LKB1) and/or Kelch-like ECH-associated protein 1 (KEAP1), have been found to exhibit reduced responsiveness to these therapeutic strategies, as revealed by multiomics analyses identifying immunosuppressed phenotypes. Recent advancements in various biological approaches have gradually unveiled the molecular mechanisms underlying intrinsic reprogrammed metabolism in tumor cells, which contribute to the evasion of immune responses by the tumor. Notably, metabolic alterations in glycolysis and glutaminolysis have a significant impact on tumor aggressiveness and the remodeling of the tumor microenvironment. Since glucose and glutamine are essential for the proliferation and activation of effector T cells, heightened consumption of these nutrients by tumor cells results in immunosuppression and resistance to ICI therapies. This review provides a comprehensive summary of the clinical efficacies of current therapeutic strategies against NSCLC harboring LKB1 and/or KEAP1 mutations, along with the metabolic alterations in glycolysis and glutaminolysis observed in these cancer cells. Furthermore, ongoing trials targeting these metabolic alterations are discussed as potential approaches to overcome the extremely poor prognosis associated with this type of cancer.

    DOI: 10.3389/fonc.2023.1249237

    Web of Science

    Scopus

    PubMed

  4. Artificial intelligence in a prediction model for postendoscopic retrograde cholangiopancreatography pancreatitis. Reviewed International journal

    Hidekazu Takahashi, Eizaburo Ohno, Taiki Furukawa, Kentaro Yamao, Takuya Ishikawa, Yasuyuki Mizutani, Tadashi Iida, Yoshimune Shiratori, Shintaro Oyama, Junji Koyama, Kensaku Mori, Yuichiro Hayashi, Masahiro Oda, Takahisa Suzuki, Hiroki Kawashima

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society     2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: In this study we aimed to develop an artificial intelligence-based model for predicting postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). METHODS: We retrospectively reviewed ERCP patients at Nagoya University Hospital (NUH) and Toyota Memorial Hospital (TMH). We constructed two prediction models, a random forest (RF), one of the machine-learning algorithms, and a logistic regression (LR) model. First, we selected features of each model from 40 possible features. Then the models were trained and validated using three fold cross-validation in the NUH cohort and tested in the TMH cohort. The area under the receiver operating characteristic curve (AUROC) was used to assess model performance. Finally, using the output parameters of the RF model, we classified the patients into low-, medium-, and high-risk groups. RESULTS: A total of 615 patients at NUH and 544 patients at TMH were enrolled. Ten features were selected for the RF model, including albumin, creatinine, biliary tract cancer, pancreatic cancer, bile duct stone, total procedure time, pancreatic duct injection, pancreatic guidewire-assisted technique without a pancreatic stent, intraductal ultrasonography, and bile duct biopsy. In the three fold cross-validation, the RF model showed better predictive ability than the LR model (AUROC 0.821 vs. 0.660). In the test, the RF model also showed better performance (AUROC 0.770 vs. 0.663, P = 0.002). Based on the RF model, we classified the patients according to the incidence of PEP (2.9%, 10.0%, and 23.9%). CONCLUSION: We developed an RF model. Machine-learning algorithms could be powerful tools to develop accurate prediction models.

    DOI: 10.1111/den.14622

    Web of Science

    Scopus

    PubMed

  5. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. Reviewed International journal

    Reiko Matsuzawa, Masahiro Morise, Fumie Kinoshita, Ichidai Tanaka, Junji Koyama, Tomoki Kimura, Yasuhiro Kondoh, Taro Tanaka, Koichiro Shima, Tetsunari Hase, Keiko Wakahara, Makoto Ishii, Naozumi Hashimoto

    Journal of cancer research and clinical oncology   Vol. 149 ( 7 ) page: 3885 - 3893   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: We determined the clinical relevance of early C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) change in blood as surrogate markers of pro-tumor inflammation (PTI) for predicting clinical outcome of programmed cell death (PD)-1/programmed cell death ligand (PD-L) 1 inhibitor treatment in non-small-cell lung carcinoma (NSCLC). METHODS: We retrospectively reviewed NSCLC patients treated with anti-PD-1 or PD-L1 inhibitors. Early CRP change was defined as the ratio of 6 weeks CRP to baseline CRP, and early NLR change was defined as that of the 6 weeks NLR to baseline NLR. PTI index was determined by combinatorial evaluation of early CRP change and early NLR change, PTI index low: both of these were low, intermediate: either of these was low, high; both of these were high. RESULTS: The study included 217 patients. Early CRP change and early NLR change were both associated with PFS and OS. The combinatorial evaluation using these two markers enabled the clear stratification of PFS and OS. The median PFS in patient with PTI index low was 13.9 months, while the median PFS in those with PTI index high was 2.5 months (p < 0.01, log-rank test). The median OS in patients with PTI index low was not reached; the median OS in those with PTI index high was only 15.4 months (p < 0.01, log-rank test). CONCLUSIONS: The combinatorial early CRP change and early NLR change as PTI biomarkers have clinical potential in identifying NSCLC patients who can achieve a durable response and long-term survival using PD-1/PD-L1 inhibitors.

    DOI: 10.1007/s00432-022-04300-x

    Web of Science

    Scopus

    PubMed

  6. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Reviewed International journal

    Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio

    Thoracic cancer   Vol. 14 ( 2 ) page: 168 - 176   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non-small cell lung cancer; however, it is unclear whether the same is applicable for small cell lung cancer (SCLC). We evaluated the efficacy of second-line amrubicin (AMR) following first-line platinum-based chemotherapy and ICI combination therapy (chemo-ICI) in SCLC. PATIENTS AND METHODS: We retrospectively enrolled consecutive patients with SCLC treated with AMR as a second-line following chemo-ICI as first-line between July 2019 and April 2021 from 16 institutions throughout Japan. We investigated the therapeutic effectiveness, safety, and efficacy-enhancing variables of AMR. RESULTS: Overall, 89 patients treated with AMR after first-line chemo-ICI were analyzed. The overall response rate (ORR) was 29.2% (95% confidence intervals [CI], 20.1-39.8) and median PFS (m PFS) was 2.99 months (95% CI, 2.27-3.65). Patients who relapsed more than 90 days after receiving first-line platinum combination therapy (sensitive relapse) exhibited greater ORR (58.3% vs. 24.7%, p = 0.035) and m PFS (5.03 vs. 2.56 months, p = 0.019) than patients who relapsed in <90 days (refractory relapse). Grade 3 or higher adverse events were mainly hematological toxicity. CONCLUSIONS: Our study suggested that the therapeutic effect of AMR was not enhanced after ICI on SCLC. However, AMR may be effective in cases of sensitive relapse after chemo-ICI. There was no increase in severe toxicity associated with AMR after ICI.

    DOI: 10.1111/1759-7714.14729

    Web of Science

    Scopus

    PubMed

  7. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. International journal

    Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Naozumi Hashimoto

    BMC cancer   Vol. 22 ( 1 ) page: 654 - 654   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Osimertinib-the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in patients with brain metastasis; however, its efficacy against other distant metastatic organs, including bone and liver, remains unclear. Therefore, we retrospectively analyzed the clinical efficacy of osimertinib in these patients in comparison to other EGFR-TKIs. METHODS: Clinical data of patients with advanced NSCLC receiving gefitinib/erlotinib (n = 183), afatinib (n = 55), or osimertinib (n = 150) at five medical institutions were retrospectively assessed for progression-free survival (PFS), overall survival (OS), and best overall response rate (ORR). RESULTS: In univariate and multivariate analyses, most distant metastases, including the brain and bone, were unrelated to the therapeutic efficacy of osimertinib, although liver metastasis and L858R mutation were independently associated with shorter PFS. PFS and OS in patients with liver metastases were significantly shorter than those in patients without liver metastases (PFS: 7.4 vs. 19.7 months, OS: 12.1 months vs. not reached, respectively). Osimertinib provided significantly longer PFS in patients with brain or bone metastasis and exon 19 deletion than the other EGFR-TKIs. The PFS of patients with liver metastases was not significantly different among the three EGFR-TKI groups. Furthermore, the ORR of osimertinib in patients with liver metastases was significantly attenuated, and the effectiveness was similar to 1st- or 2nd -generation EGFR-TKIs. CONCLUSION: Osimertinib provided better clinical benefits than 1st- and 2nd-generation EGFR-TKIs for patients with EGFR-mutant NSCLC, particularly those with brain or bone metastases and exon 19 deletion; however, its efficacy against liver metastasis was remarkably attenuated. New therapeutic developments for patients with EGFR-mutant NSCLC with liver metastases are needed.

    DOI: 10.1186/s12885-022-09741-8

    Web of Science

    Scopus

    PubMed

  8. Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer

    Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

    Internal Medicine   Vol. 61 ( 5 ) page: 703 - 708   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <p>Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a <i>BRAF V600E</i> mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with <i>BRAF V600E</i> mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression. </p>

    DOI: 10.2169/internalmedicine.6657-20

    Web of Science

    Scopus

    PubMed

    CiNii Research

  9. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. International journal

    Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katuyuki Kiura, Yuta Takashima, Seiji Yano, Junji Koyama, Takahiro Fukushima, Junko Hamamoto, Hideki Terai, Shinnosuke Ikemura, Ryo Takemura, Koichi Goto, Kenzo Soejima

    Lung cancer (Amsterdam, Netherlands)   Vol. 162   page: 140 - 146   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective clinical trials. In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. MATERIALS AND METHODS: From August 2018 to January 2020, 14 NSCLC patients with EGFR ex20ins were enrolled, of whom 2 were excluded because they did not meet the inclusion criteria. Efficacy and safety of 80 mg osimertinib were evaluated. In addition, we performed a translational exploratory study to clarify the association of mutation type-specific drug sensitivity, osimertinib pharmacokinetic data, and clinical efficacy. RESULTS: Of the evaluated patients, none experienced objective response, 7 experienced stable disease (58.3%), and 5 experienced disease progression (41.7%). The median progression free survival (PFS) was 3.8 months, and the median overall survival was 15.8 months. Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. CONCLUSIONS: Regular dose, 80 mg/day, of osimertinib has limited clinical activity in NSCLC patients with EGFR ex20ins. The translational study proposed the potential efficacy of higher dose osimertinib in a subgroup of EGFR ex20ins-positive NSCLC.

    DOI: 10.1016/j.lungcan.2021.10.006

    Web of Science

    Scopus

    PubMed

  10. Is area under the curve the best parameter for carboplatin induced emetic risk stratification?

    Sachiko Ozone, Kazuya Ichikawa, Masahiro Morise, Akira Matsui, Fumie Kinoshita, Reiko Matsuzawa, Junji Koyama, Ichidai Tanaka, Naozumi Hashimoto

    Nagoya journal of medical science   Vol. 83 ( 4 ) page: 773 - 785   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Carboplatin (CBDCA)-induced emetic risk is currently classified on the basis of CBDCA-area under the curve (CBDCA-AUC). We investigated the utility of three CBDCA dosage parameters for predicting emesis by CBDCA. Patients with thoracic cancer treated with CBDCA were included. The endpoints were complete response (CR) and total control (TC). CR was defined as no vomiting and no use of rescue medication during the overall assessment period, whereas TC was defined as no vomiting, nausea, nor use of rescue medication during the overall assessment period. The parameters of CBDCA were defined as follows: (1) CBDCA-AUC; (2) CBDCA/body surface area (BSA): the administered dose of CBDCA per body surface area (mg/m2); and (3) total CBDCA/body: the total administered dose of CBDCA (mg). Eighty-five patients were evaluated. The median CBDCA/BSA but not CBDCA-AUC was higher in patients with non-CR compared to those with CR. Receiver operating characteristic curve analysis revealed that the AUC of CBDCA/BSA for predicting non-CR was higher than that of CBDCA-AUC. CBDCA/BSA shows greater potential for predicting CBDCA-induced emetic risk compared with CBDCA-AUC, which is the parameter in current antiemetic guidelines.

    DOI: 10.18999/nagjms.83.4.773

    Web of Science

    Scopus

    PubMed

  11. Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)

    Ariyasu Ryo, Uchibori Ken, Tanaka Hisashi, Miyauchi Eisaku, Kawashima Yosuke, Ohyanagi Fumiyoshi, Horiike Atsushi, Sakatani Toshio, Saiki Masafumi, Tambo Yuichi, Tanimoto Azusa, Sonoda Tomoaki, Koyama Junji, Uenami Takeshi, Kudo Keita, Tsuchiya Yuko, Nishio Makoto

    Haigan   Vol. 60 ( 7 ) page: 966 - 971   2020.12

     More details

    Language:Japanese   Publisher:The Japan Lung Cancer Society  

    <p><b><i>Objective. </i></b>In clinical practice, durvalumab has been used as a standard maintenance treatment after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (NSCLC). However, it is unknown as to how often practitioners avoid using durvalumab. The present study aimed to analyze the factors that influence decision-making in relation to the administration of durvalumab. <b><i>Methods. </i></b>We retrospectively analyzed the treatment of locally advanced NSCLC in 12 hospitals with lung cancer specialists. We evaluated patients with NSCLC who were treated with CRT from May 2018 to December 2019 and compared the characteristics between patients who received durvalumab and those who did not. We also conducted a questionnaire-based survey to determine the reasons for avoidingdurvalumab.<b><i>Results. </i></b>Among199patientswhoreceivedCRT,durvalumabwas administered to 169 patients (84.9%). The median age of the patients in the non-administration group was significantly higher than that in the administration group (70 vs. 67 years, p=0.0465), and the performance status (PS) ≥1 in the non-administration group was significantly higher than that in the administration group (65.5 vs. 40.4%, p=0.0148). According to the questionnaire responses, durvalumab administration was avoided for the following reasons: adverse events due to CRT (n=7); patient needs (n=5); disease progression (n=4); poor PS (n=3); driver mutation of NSCLC (n=3); and complications of autoimmune disease (n=2). <b><i>Conclusion. </i></b>Durvalumab was administered to 84.9% of patients in this study. Each practitioner considered age, PS, adverse events due to CRT, and driver mutations of NSCLC, before prescribing durvalumab.</p>

    DOI: 10.2482/haigan.60.966

    Scopus

    CiNii Research

  12. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer. International journal

    Akira Matsui, Masahiro Morise, Ichidai Tanaka, Sachiko Ozone, Reiko Matsuzawa, Junji Koyama, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa

    Cancer investigation   Vol. 38 ( 7 ) page: 424 - 430   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10-20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

    DOI: 10.1080/07357907.2020.1793350

    Web of Science

    Scopus

    PubMed

  13. Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors". International journal

    Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto, Yoshinori Hasegawa

    Clinical lung cancer   Vol. 21 ( 3 ) page: E205 - E205   2020.5

     More details

  14. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. International journal

    Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto, Yoshinori Hasegawa

    Clinical lung cancer   Vol. 20 ( 6 ) page: 442 - +   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Pneumonitis is one of the immune-related adverse events of programmed death 1 (PD-1) inhibitors that sometimes cause lethal outcomes. Although some recent reports have described PD-1 inhibitors as more effective in non-small-cell lung cancer (NSCLC) patients with immune-related adverse events than in those without, few data are available on the prognosis of those treated with PD-1 inhibitors who developed immune-related pneumonitis (IRP). Additionally, the robust risk factors of IRP have not been well elucidated. PATIENTS AND METHODS: A retrospective review of patients with recurrent or advanced NSCLC who took a PD-1 inhibitor (nivolumab or pembrolizumab monotherapy) between January 2016 and March 2018 was undertaken. Radiologic findings such as unilateral infiltration were also defined as IRP as long as they were deemed relevant to PD-1 inhibitors. RESULTS: Twenty-seven (16%) of 170 patients developed IRP. Although 22 (81%) of 27 patients with IRP recovered with drug cessation with or without corticosteroid therapy, 8-week landmark analysis showed the overall survival after administration of the PD-1 inhibitor was significantly shorter in patients with IRP than in those without (8.7 vs. 23.0 months, P = .015). Patients with IRP tended to not receive next-line treatment and choose best supportive care after cessation of PD-1 inhibitor therapy. In the multivariate analysis, pembrolizumab (vs. nivolumab) and low serum albumin were independent risk factors for IRP. CONCLUSION: Development of IRP was correlated with poor prognosis in patients with NSCLC. Further study is necessary for establishing the best prediction and management strategies for IRP.

    DOI: 10.1016/j.cllc.2019.07.006

    Web of Science

    Scopus

    PubMed

  15. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. International journal

    Satoru Kitazono, Kazuko Sakai, Noriko Yanagitani, Ryo Ariyasu, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Shingo Nishikawa, Ken Uchibori, Atsushi Horiike, Kazuto Nishio, Makoto Nishio

    Cancer science   Vol. 110 ( 10 ) page: 3350 - 3357   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Most patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) will inevitably develop acquired resistance induced by treatment with EGFR tyrosine kinase inhibitors (EGFR-TKI). The mechanisms of resistance to EGFR-TKI are multifactorial, and the detection of these mechanisms is critical for treatment choices in patients who have progressed after EGFR-TKI therapy. We evaluated the feasibility of a molecular barcode method using next-generation sequencing to detect multifactorial resistance mechanisms in circulating tumor DNA and compared the results with those obtained using other technologies. Plasma samples were collected from 25 EGFR mutation-positive NSCLC patients after the development of EGFR-TKI resistance. Somatic mutation profiles of these samples were assessed using two methods of next-generation sequencing and droplet digital PCR (ddPCR). The positive rate for EGFR-sensitizing mutations was 18/25 (72.0%) using ddPCR, 17/25 (68.0%) using amplicon sequencing, and 19/25 (76.0%) using molecular barcode sequencing. Rate of the EGFR T790M resistance mutation among patients with EGFR-sensitizing mutations was shown to be 7/18 (38.9%) using ddPCR, 6/17 (35.3%) using amplicon sequencing, and 8/19 (42.1%) using molecular barcode sequencing. Copy number gain in the MET gene was detected in three cases using ddPCR. PIK3CA, KRAS and TP53 mutations were detected using amplicon sequencing. Molecular barcode sequencing detected PIK3CA, TP53, KRAS, and MAP2K1 mutations. Results of the three assays were comparable; however, in cell-free DNA, molecular barcode sequencing detected mutations causing multifactorial resistance more sensitively than did the other assays.

    DOI: 10.1111/cas.14153

    PubMed

  16. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. International journal

    Masafumi Saiki, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Makoto Nishio

    Lung cancer (Amsterdam, Netherlands)   Vol. 133   page: 4 - 9   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Serum adenosine deaminase (ADA) activity is a marker of immune reaction to several diseases. We evaluated changes in serum ADA in patients with lung cancer undergoing chemotherapy or anti-programmed cell death-1 (PD-1) therapy to examine the correlation between serum ADA and the therapy efficacy. MATERIALS AND METHODS: We assessed 50 patients with advanced lung cancer receiving chemotherapy or anti-PD-1 therapy. Serum ADA was measured before and on day 7 of the first treatment cycle and day 0 of subsequent cycles. Correlations between ADA change and efficacy of treatment were evaluated. RESULTS: Of the 50 patients, 20 were treated with chemotherapy and 30 were treated with anti-PD-1 therapy. Serum ADA decreased significantly between baseline and day 7 of the first cycle in patients undergoing chemotherapy, regardless of response (partial response [PR] or stable disease [SD]: -23% [-38 to +32; p =  0.002]; progressive disease [PD]: -12% [-42 to +6; p =  0.500]). Conversely, in patients undergoing anti-PD-1 therapy, serum ADA increased significantly between baseline and 7 days after the first dose and before subsequent doses in patients who had PR or SD. (day 7 of first cycle: +6% [-10 to +34; p =  0.034], day 0 of second cycle: 8% [-5 to +37; p =  0.002], day 0 of third cycle: 9% [-3 to +55; p =  0.002]). However, serum ADA did not significant change in PD patients undergoing anti-PD-1 therapy. Furthermore, early increases in serum ADA were associated with longer progression-free survival in patients receiving anti-PD-1 therapy (p =  0.006). CONCLUSION: Changes in serum ADA could be used to predict clinical benefit from anti-PD-1 therapy in patients with lung cancer. The association between changes in serum ADA and the efficacy of ant-PD-1 therapy thus remains inconclusive and requires further study.

    DOI: 10.1016/j.lungcan.2019.04.022

    PubMed

  17. A Case of Aortic Dissection During Bronchoscopy

    Saiki Masafumi, Ohyanagi Fumiyoshi, Koyama Junji, Sonoda Tomoaki, Nishikawa Shingo, Kitazono Satoru, Yanagitani Noriko, Horiike Atsushi, Nishio Makoto

    The Journal of the Japan Society for Respiratory Endoscopy   Vol. 41 ( 3 ) page: 315 - 320   2019.5

     More details

    Language:Japanese   Publisher:The Japan Society for Respiratory Endoscopy  

    <p><b><i>Background.</i></b> Aortic dissection during bronchoscopy is a rare, albeit potentially fatal, complication. <b><i>Case.</i></b> A 68-year-old man with low-grade B-cell lymphoma who achieved complete remission with treatment in 2013 was found to have lymphadenopathy with <sup>18</sup>F-fluorodeoxyglucose accumulation in the mediastinal lymph node by positron emission computed tomography in November 2016, with suspicious recurrence. His medical history included myocardial infarction and abdominal aortic aneurysm, and bronchoscopy was performed in January 2017 for definitive diagnosis. During bronchoscopy, he complained of chest discomfort after the lidocaine spray on the trachea, and the right main bronchus. His chest discomfort continued although the procedure was stopped, and the bronchoscope was removed, and the pain spread from the chest to the back. An enhanced computed tomography acquired immediately revealed Stanford type B acute aortic dissection. The patient was transferred to a specialized facility and rescued. <b><i>Conclusion.</i></b> Special attention should be paid to patients with multiple vascular complications as illustrated in the current case of aortic dissection during bronchoscopy.</p>

    DOI: 10.18907/jjsre.41.3_315

    CiNii Research

  18. Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017. International journal

    Natsuki Takano, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Masafumi Saiki, Yosuke Kawashima, Tomoyo Oguri, Kakeru Hisakane, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Atsushi Horiike, Akihiko Gemma, Makoto Nishio

    Lung cancer (Amsterdam, Netherlands)   Vol. 131   page: 69 - 77   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: In the past two decades several antineoplastic agents have been approved for the treatment of advanced non-small-cell lung cancer (NSCLC), and the management of these patients has drastically changed. However, there is limited information regarding the impact of these advances on patient survival in clinical practice. MATERIALS AND METHODS: We analyzed the survival of patients with stage IV NSCLC who received any treatment in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) between January 1, 1995 and March 1, 2017. A total of 1,547 consecutive patients were included in this case series. In this analysis, five diagnostic periods were evaluated: 1995-1999 (period A), 2000-2004 (period B), 2005-2009 (period C), 2010-2014 (period D), and 2015-2017 (period E). We compared overall survival (OS) between the periods before and after propensity score matching (PSM) and in patients with EGFR mutation, with ALK fusion gene, or without driver mutation. RESULTS: In the past two decades the OS of patients with stage IV NSCLC improved. The median OSs for periods A, B, C, D, and E were 9.0, 11.0, 13.7, 17.9 months, and not reached, respectively. After PSM with known baseline characteristics, the trend of improvement in OS was similar. However, the OS of patients with EGFR mutation or ALK fusion gene did not improve between periods, despite the availability of several tyrosine kinase inhibitors in Japan. The OS of patients without a driver mutation was slightly longer in the period E. CONCLUSION: The introduction of new classes of drugs has significantly improved the survival of patients with stage IV NSCLC. However, the approval of similar types of drugs may not be associated with further improvement in survival.

    DOI: 10.1016/j.lungcan.2019.03.008

    PubMed

  19. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. International journal

    Junji Koyama, Atsushi Horiike, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Masafumi Saiki, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio

    Journal of thoracic disease   Vol. 11 ( 5 ) page: 1919 - 1928   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Recent studies have suggested a correlation between immune-related thyroid dysfunction (irTD) and the superior efficacy of anti-programmed cell death protein-1 (anti-PD-1) treatment in non-small cell lung cancer (NSCLC). Embryologically, the lung and thyroid are similar in origin, and thyroid transcription factor-1 (TTF-1) expresses in both organs, including NSCLC. We explored our hypothesis that TTF-1 expression in NSCLC might correlate with irTD incidence and anti-PD-1 treatment efficacy. METHODS: We identified 132 patients with NSCLC treated with anti-PD-1 antibody at our hospital between December 2015 and June 2017. We evaluated TTF-1 expression in tumor by immunohistochemistry using a mouse monoclonal antibody (clone 8G7G3/1, 1:100, Dako). IrTD was defined as two or more successive abnormal levels of thyroid-stimulating hormone (TSH) during anti-PD-1 treatment. We retrospectively assessed correlations between TTF-1 expression in tumor, irTD incidence, and anti-PD-1 treatment efficacy. RESULTS: Of 132 patients, 67 (51%) and 65 (49%) were positive and negative for TTF-1, respectively. We observed irTD in 19 patients (6 positives and 13 negatives for TTF-1). The incidence of irTD was 9% and 20% in TTF-1-positive and TTF-1-negative NSCLCs, respectively (P=0.086). Particularly, in non-squamous (NSQ) cell carcinomas, the irTD incidence was significantly higher in patients negative for TTF-1 (30%) than in those positive for TTF-1 (9%; P=0.010), and TTF-1 expression was identified as a significant risk factor for irTD on multivariate logistic regression analysis [odds ratio (OR), 0.18; 95% confidence interval (CI), 0.05-0.59; P=0.005]. Furthermore, longer median progression-free survival (10.3 months) was observed in patients with TTF-1-negative NSCLC with irTD compared to those with TTF-1-positive NSCLC with irTD, TTF-1-positive NSCLC without irTD, and TTF-1-negative NSCLC without irTD (4.2, 1.4, and 2.4 months, respectively). CONCLUSIONS: TTF-1 expression in NSCLC might correlate with irTD and anti-PD-1 treatment efficacy.

    DOI: 10.21037/jtd.2019.04.102

    PubMed

  20. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer. International journal

    Masafumi Saiki, Satoru Kitazono, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Katsunori Oikado, Hironori Ninomiya, Kengo Takeuchi, Yuichi Ishikawa, Makoto Nishio

    Clinical lung cancer   Vol. 19 ( 5 ) page: 435 - 440   2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Rearranged during transfection (RET)-rearranged non-small-cell lung cancer (NSCLC) is relatively rare and the clinical and computed tomography (CT) image characteristics of patients with an advanced disease stage have not been well documented. PATIENTS AND METHODS: We identified patients with advanced-stage RET-rearranged NSCLC treated in the Cancer Institute Hospital, Japanese Foundation for Cancer Research, and analyzed the clinical and CT imaging characteristics. RESULTS: In 21 patients with advanced RET-rearranged NSCLC, RET rearrangements were identified using fluorescence in situ hybridization and/or reverse transcriptase-polymerase chain reaction. The fusion partner genes were identified as KIF5B (57%), CCDC6 (19%), and unknown (24%). CT imaging showed that 12 primary lesions (92%) were peripherally located and all were solid tumors without ground-glass, air bronchograms, or cavitation. The median size of the primary lesions was 30 mm (range, 12-63 mm). Of the 18 patients with CT images before initial chemotherapy, 12 (67%) showed an absence of lymphadenopathy. Distant metastasis included 13 with pleural dissemination (72%), 10 with lung metastasis (56%), 8 with bone metastasis (44%), and 2 with brain metastasis (11%). CONCLUSION: Advanced RET-rearranged NSCLC manifested as a relatively small and peripherally located solid primary lesion with or without small solitary lymphadenopathy. Pleural dissemination was frequently observed.

    DOI: 10.1016/j.cllc.2018.04.006

    PubMed

  21. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. International journal

    Ryo Ariyasu, Shingo Nishikawa, Ken Uchibori, Tomoko Oh-Hara, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Naohiko Inase, Kazuo Kasahara, Makoto Nishio, Ryohei Katayama

    Lung cancer (Amsterdam, Netherlands)   Vol. 117   page: 1 - 6   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that can overcome resistance due to the Thr790Met (T790M) mutation. However, osimertinib occasionally shows limited efficacy in a small population of patients. We investigated the correlation between the ratio of T790M to EGFR activating mutation and the response to osimertinib. MATERIALS AND METHODS: Between April 2016 and April 2017, 44 patients started osimertinib therapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. We performed EGFR mutation analysis of cytological samples from 33 patients using droplet digital PCR. We calculated the ratio of T790M to EGFR activating mutations and correlated it with the systemic response to osimertinib. RESULTS: In tumors from the 33 patients, the average ratio of T790M to EGFR activating mutations was 0.420. Twenty-one of the 33 patients had tumors with a T790M ratio of ≥0.4. The osimertinib response rate was significantly higher (92.3%) in patients with a T790M ratio of ≥0.4 than in those with a T790M ratio of <0.4 (52.6%; p = 0.0237). We examined the correlation between the T790M ratio and the tumor reduction rate and obtained a coefficient of r = 0.417 (p = 0.0175). In patients with a T790M ratio of ≥0.4, the median progression-free survival was 355 days, which was longer, but not significant, than that in patients with a T790M ratio of <0.4 (median: 264 days). In patients with a T790M ratio of ≥0.4, the median treatment duration from first-line therapy onward was 931 days, which was significantly longer than that in patients with a T790M ratio of <0.4 (median, 567.5 days) (p = 0.044). CONCLUSION: The T790M ratio to EGFR activating mutation in tumor may correlate with the response to osimertinib, and patients with a higher T790M ratio have a longer treatment history.

    DOI: 10.1016/j.lungcan.2017.12.018

    PubMed

  22. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer. International journal

    Tomoaki Sonoda, Shingo Nishikawa, Rie Sakakibara, Masafumi Saiki, Ryo Ariyasu, Junji Koyama, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio

    Respiratory medicine case reports   Vol. 24   page: 19 - 21   2018

     More details

    Language:English  

    In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%-65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%-14% of these cases transformed to small cell lung cancer (SCLC). Generally, the EGFR T790M secondary mutation develops with ongoing ATP competitive inhibition. We present a case of a 76-year-old woman with lung adenocarcinoma harboring an EGFR-L858R mutation who received first-line gefitinib and developed SCLC transformation. She was administered several chemotherapy agents, including a platinum doublet. The primary lesion that showed SCLC transformation had reconverted to adenocarcinoma with EGFR L858R and T790M mutations at the time of a second re-biopsy. Therefore, she was administered osimertinib, which resulted in clinical remission. This case suggested that serial biopsies are necessary even after SCLC transformation.

    DOI: 10.1016/j.rmcr.2018.03.009

    PubMed

  23. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. International journal

    Masafumi Saiki, Fumiyoshi Ohyanagi, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio

    Japanese journal of clinical oncology   Vol. 47 ( 12 ) page: 1189 - 1192   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Inflammatory myofibroblastic tumor (IMT) is a neoplasm characterized by the proliferaton of myofibroblasts with the infiltration of inflammatory cells. There is no standard treatment for patients with recurrent or metastatic IMT. We describe here a patient with hyper-progressive IMT with an anaplastic lymphoma kinase (ALK) fusion gene that dramatically responded to alectinib without adverse events. His dramatic and enduring response supports the observation that alectinib may be considered a good treatment option for rare aggressive ALK-positive tumors.

    DOI: 10.1093/jjco/hyx133

    PubMed

  24. Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. International journal

    Ryo Ariyasu, Atsushi Horiike, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio

    Anticancer research   Vol. 37 ( 8 ) page: 4229 - 4232   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs. PATIENTS AND METHODS: Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected. RESULTS: Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case. CONCLUSION: Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms.

    PubMed

  25. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib. International journal

    Ryo Ariyasu, Atsushi Horiike, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Yosuke Kawashima, Natsuki Takano, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio

    Anti-cancer drugs   Vol. 28 ( 5 ) page: 565 - 567   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled. This combination treatment may be useful to treat LMC in patients with EGFR-positive non-small-cell lung cancer.

    DOI: 10.1097/CAD.0000000000000489

    PubMed

  26. The Treatment of Coexisting Lung Cancer and <i>Mycobacterium avium</i> Complex Infection with Gefitinib, Rifabutin, Clarithromycin, and Ethambutol, Concomitant with the Measurement of the Blood Gefitinib Concentration: a Case Report

    Ito Hiroshi, Nakane Shigeki, Nakamura Saya, Koyama Junji, Machida Kazuhiko, Matsuo Masaki

    Haigan   Vol. 56 ( 5 ) page: 355 - 360   2016

     More details

    Language:Japanese   Publisher:The Japan Lung Cancer Society  

    <p><b><i>Background. </i></b>As the incidence of lung cancer and pulmonary non-tuberculous mycobacterial (NTM) infection is increasing, the incidence of coexistent lung cancer and pulmonary NTM infection is also increasing. Evidence shows that drug interactions can be problematic in the treatment of coexisting lung cancer and pulmonary NTM infection. Gefitinib is normally used to treat lung cancer. However, CYP3A4 inducers, such as rifampicin and rifabutin, reduce the concentration of gefitinib in the blood, whereas CYP3A4 inhibitors, such as clarithromycin, increase its concentration. Consequently, drug interaction is a major problem when gefitinib is used to treat lung cancer in patients with progressive pulmonary NTM infection. <b><i>Case. </i></b>A 72-year-old man was diagnosed with stage IV lung cancer. The cancer was pathologically identified as an adenocarcinoma, and a driver mutation of the epidermal growth factor receptor (L858R) was identified. The patient was treated with gefitinib, but he subsequently developed a progressive pulmonary <i>Mycobacterium avium</i> infection. We also identified drug interactions between gefitinib and rifampicin, rifabutin and clarithromycin. The patient's blood gefitinib concentration was measured because combination therapy with these drugs can lead to instability in the concentration of gefitinib and tumor progression. The gefitinib concentration was reduced to 60% of the original concentration following the administration of rifabutin but increased to 130% of the original concentration after the administration of rifabutin, clarithromycin, and ethambutol. However, the patient developed hyperbilirubinemia after the combined administration of rifabutin, clarithromycin, and ethambutol, and as a consequence, the combination therapy was discontinued. Afatinib is a drug that is largely considered to be unaffected by the CYP3A4 metabolism. Thus, afatinib was administered with clarithromycin, ethambutol, and rifampicin; however, the patient experienced side effects and the therapy was discontinued. <b><i>Conclusion. </i></b>We herein presented a case of a patient with coexisting lung cancer and pulmonary <i>Mycobacterium avium</i> complex disease, who was treated with gefitinib, rifabutin, clarithromycin, and ethambutol. However, this combination therapy resulted in both drug interactions and side effects. It is therefore very important to consider drug interactions and side effects in the treatment of coexisting lung cancer and pulmonary NTM infection.</p>

    DOI: 10.2482/haigan.56.355

    CiNii Research

  27. Malignant Pleural Mesothelioma with Extensive Invasion of the Spinal Canal

    Koyama Junji, Yokoi Eito, Wada Yukiko, Ito Hiroshi, Machida Kazuhiko, Matsuo Masaki

    Haigan   Vol. 56 ( 7 ) page: 1022 - 1027   2016

     More details

    Language:Japanese   Publisher:The Japan Lung Cancer Society  

    <p><b><i>Background. </i></b>Malignant pleural mesothelioma often spreads locally into the adjacent tissues. However, it rarely invades the spinal canal. <b><i>Case. </i></b>In May 2007, a 69-year-old man presented with an abnormal shadow on a chest X-ray, and was diagnosed with malignant pleural mesothelioma of the right lung (epithelioid-type). He underwent various treatments, including chemotherapy and thermotherapy. However, he developed chest and back pain on the right-hand side and weakness of both lower extremities. He was therefore admitted to our hospital in September 2014. After admission, he developed paraplegia of the lower extremities and bladder and rectal disturbance. Spinal magnetic resonance imaging (MRI) showed that the tumor had invaded the cervical, thoracic, and lumbar epidural space through the Th8/9 intervertebral foramen. His neurological symptoms were temporarily improved by the administration of a corticosteroid. However, he died of respiratory failure due to tumor progression approximately 2 months after admission. On pathological autopsy the malignant pleural mesothelioma was observed to have extensively invaded the epidural space and the spinal dura mater. <b><i>Conclusion. </i></b>Malignant pleural mesothelioma can invade the spinal canal through the intervertebral foramen. When a patient with malignant pleural mesothelioma develops radicular symptoms, such as radiating pain, paralysis, and numbness, physicians should consider the possibility that the tumor has invaded the spinal canal.</p>

    DOI: 10.2482/haigan.56.1022

    CiNii Research

▼display all

MISC 60

  1. Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs

    Yamaguchi, T; Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Koyama, J; Kuwatsuka, Y; Goto, Y; Imaizumi, K; Itani, H; Zenke, Y; Oki, M; Ishii, M

    ANNALS OF ONCOLOGY   Vol. 34   page: S1678 - S1678   2023.11

  2. 非小細胞肺癌に対する初回Chemo+ICI併用療法後のDTX+RAMの多施設共同第II相試験 SCORPION試験

    伊藤 健太郎, 松澤 令子, 森瀬 昌宏, 畑地 治, 高橋 孝輔, 神山 潤二, 鍬塚 八千代, 後藤 康洋, 今泉 和良, 井谷 英敏, 山口 哲平, 善家 義貴, 沖 昌英, 石井 誠

    肺癌   Vol. 63 ( 5 ) page: 542 - 542   2023.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  3. ステロイド抵抗性の免疫関連有害事象に対する免疫抑制剤の有効性(TOPGAN2022-01)

    春谷 勇平, 小楠 真典, 戸塚 猛大, 齋藤 良太, 神山 潤二, 坂本 博昭, 園田 智明, 土屋 裕子, 大場 智広, 工藤 慶太, 行徳 宏, 中富 克己, 有安 亮

    肺癌   Vol. 63 ( 5 ) page: 529 - 529   2023.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  4. 肺原発Hepatoid Adenocarcinomaに化学放射線療法後のDurvalumabが長期奏効した一例

    橋本 賢彦, 神山 潤二, 森瀬 昌宏, 平野 達也, 大曽根 祥子, 速井 俊策, 田中 一大, 若原 恵子, 石井 誠, 関 雅文, 中黒 匡人, 加留部 謙之輔

    肺癌   Vol. 63 ( 5 ) page: 700 - 700   2023.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  5. 肺癌微小検体における組織学的サブタイプとPD-1/PD-L1阻害剤の有効性との関連

    平野 達也, 森瀬 昌宏, 堀 翔, 橋本 賢彦, 大曽根 祥子, 速井 俊策, 神山 潤二, 田中 一大, 佐藤 光夫, 木村 智樹, 近藤 康博, 石井 誠

    肺癌   Vol. 63 ( 5 ) page: 469 - 469   2023.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  6. ICI 機械学習を活用した抗PD-1/PD-L1抗体治療の生存予測バイオマーカー構築

    神山 潤二, 森瀬 昌宏, 古川 大記, 阪本 考司, 松下 明弘, 松尾 正樹, 浅野 周一, 田中 太郎, 島 浩一郎, 木村 智樹, 近藤 康博, 石井 誠

    日本呼吸器学会誌   Vol. 12 ( 増刊 ) page: 168 - 168   2023.3

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  7. Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer

    Koyama, J; Morise, M; Furukawa, T; Oyama, S; Matsuzawa, R; Tanaka, I; Wakahara, K; Yokota, H; Kimura, T; Shiratori, Y; Kondoh, Y; Hashimoto, N

    RESPIROLOGY   Vol. 28   page: 39 - 40   2023.2

     More details

  8. 進行非小細胞肺癌における臨床および画像特徴量を用いた機械学習による個別化生存予測モデルの構築

    神山 潤二, 森瀬 昌宏, 古川 大記, 松澤 令子, 田中 一大, 横田 秀夫, 木村 智樹, 近藤 康博, 橋本 直純, 石井 誠

    肺癌   Vol. 62 ( 6 ) page: 711 - 711   2022.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  9. 単発副腎転移に対し化学療法後に切除し長期の無病生存期間が得られた肺腺癌の1例

    飯島 淳司, 松澤 令子, 森瀬 昌宏, 田中 一大, 平野 達也, 佐藤 美佳, 神山 潤二, 柴田 寛史, 玄 崇永, 米田 一樹, 堀 和美, 長谷 哲成, 橋本 直純, 後藤 真輝, 中村 彰太, 芳川 豊史

    肺癌   Vol. 62 ( 2 ) page: 169 - 169   2022.4

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  10. 実臨床でのDurvalumab投与可否のDecision Making Factorに関する検討

    上浪 健, 田中 寿志, 宮内 栄作, 川嶋 庸介, 大柳 文義, 齊木 雅史, 酒谷 俊雄, 堀池 篤, 有安 亮, 谷本 梓, 丹保 裕一, 園田 智明, 神山 潤二, 工藤 慶太, 土屋 裕子, 西尾 誠人

    肺癌   Vol. 60 ( 6 ) page: 661 - 661   2020.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  11. 非小細胞肺癌の組織診断と免疫チェックポイント阻害剤の治療効果の検討

    堀 翔, 森瀬 昌宏, 松澤 令子, 神山 潤二, 田中 一大, 長谷 哲成, 進藤 有一郎, 若原 恵子, 橋本 直純, 長谷川 好規

    日本呼吸器学会誌   Vol. 9 ( 増刊 ) page: 216 - 216   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  12. PS不良の進行再発非小細胞肺癌に対する免疫チェックポイント阻害薬

    神山 潤二, 森瀬 昌宏, 松澤 令子, 田中 太郎, 浅野 周一, 田中 一大, 長谷 哲成, 木村 智樹, 島 浩一郎, 近藤 康博, 橋本 直純, 長谷川 好規

    日本呼吸器学会誌   Vol. 9 ( 増刊 ) page: 172 - 172   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  13. 抗PD-1/PD-L1抗体治療を受けた非小細胞肺癌患者における転移臓器部位・数の予後への影響

    松澤 令子, 森瀬 昌宏, 神山 潤二, 木村 智樹, 近藤 康博, 橋本 直純, 長谷川 好規

    日本呼吸器学会誌   Vol. 9 ( 増刊 ) page: 257 - 257   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  14. 抗PD-1/PD-L1抗体治療を受けた非小細胞肺癌患者における転移臓器部位の予後への影響

    松澤 令子, 森瀬 昌宏, 神山 潤二, 木村 智樹, 近藤 康博, 橋本 直純

    肺癌   Vol. 59 ( 6 ) page: 703 - 703   2019.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  15. Performance status不良の進行再発非小細胞肺癌に対する免疫チェックポイント阻害薬の有効性と安全性

    神山 潤二, 森瀬 昌宏, 松澤 令子, 田中 一大, 長谷 哲成, 木村 智樹, 近藤 康博, 橋本 直純

    肺癌   Vol. 59 ( 6 ) page: 777 - 777   2019.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  16. Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC

    Matsuzawa, R; Morise, M; Tanaka, I; Koyama, J; Kimura, T; Kondoh, Y; Hase, T; Sakamoto, K; Hashimoto, N; Hasegawa, Y

    JOURNAL OF THORACIC ONCOLOGY   Vol. 14 ( 10 ) page: S716 - S716   2019.10

  17. Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status

    Koyama, J; Kimura, T; Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Kataoka, K; Matsuzawa, R; Fukihara, J; Sakamoto, K; Morise, M; Hashimoto, N; Kondoh, Y; Hasegawa, Y

    ANNALS OF ONCOLOGY   Vol. 30   page: 141 - 141   2019.10

  18. Pembrolizumabによる薬剤性肝障害が疑われた1例

    佐藤 智則, 後藤 洋輔, 神山 潤二, 山野 泰彦, 横山 俊樹, 松田 俊明, 片岡 健介, 木村 智樹, 近藤 康博, 西川 和希, 新家 卓郎, 鈴木 康彦

    肺癌   Vol. 59 ( 2 ) page: 191 - 192   2019.4

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  19. 特発性PPFEにおける健康関連QOLと各臨床指標の関連についての検討

    森 裕太, 神山 潤二, 寺町 涼, 山野 泰彦, 横山 俊樹, 松田 俊明, 片岡 健介, 木村 智樹, 近藤 康博

    日本呼吸器学会誌   Vol. 8 ( 増刊 ) page: 322 - 322   2019.3

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  20. 当院におけるnon HIV-ニューモシスティス肺炎(PCP)の検討

    野口 陽一朗, 片岡 健介, 木村 智樹, 松田 俊明, 横山 俊樹, 山野 泰彦, 神山 潤二, 寺町 涼, 近藤 康博

    日本呼吸器学会誌   Vol. 8 ( 増刊 ) page: 203 - 203   2019.3

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器学会  

  21. 非小細胞性肺癌に対する免疫チェックポイント阻害薬投与症例の効果予測因子の検討

    野口 陽一朗, 大井 肇, 速井 俊策, 近藤 康博, 木村 智樹, 片岡 健介, 松田 俊明, 横山 俊樹, 山野 泰彦, 神山 潤二, 寺町 涼

    肺癌   Vol. 58 ( 6 ) page: 747 - 747   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  22. PPFEに対するリハビリテーションの現状について

    森 裕太, 神山 潤二, 寺町 涼, 山野 泰彦, 横山 俊樹, 松田 俊明, 片岡 健介, 木村 智樹, 近藤 康博

    日本呼吸ケア・リハビリテーション学会誌   Vol. 28 ( Suppl. ) page: 203s - 203s   2018.10

     More details

    Language:Japanese   Publisher:(一社)日本呼吸ケア・リハビリテーション学会  

  23. 当院で経験したN0非小細胞肺癌に対する定位放射線療法の検討

    大井 肇, 近藤 康博, 木村 智樹, 片岡 健介, 松田 俊明, 横山 俊樹, 神山 潤二, 寺町 涼, 橋爪 知紗

    肺癌   Vol. 58 ( 6 ) page: 628 - 628   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  24. 抗PD-1抗体による薬剤性肺障害と呼吸機能の関連

    神山 潤二, 木村 智樹, 石原 寛之, 佐藤 智則, 大井 肇, 森 裕太, 萩本 聡, 後藤 洋輔, 武井 玲生仁, 寺町 涼, 山野 泰彦, 横山 俊樹, 松田 俊明, 片岡 健介, 近藤 康博

    肺癌   Vol. 58 ( 6 ) page: 710 - 710   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  25. Cancer Board Conference 気管食道ステントを挿入し、経口摂取可能となった肺がんから気管食道瘻を併発した1例

    櫻井 宏樹, 中山 博文, 神山 潤二, 志賀 太郎, 松枝 清, 中山 耕之介, 佐伯 吉規

    Cancer Board Square   Vol. 4 ( 2 ) page: 183 - 203   2018.7

  26. 気管支鏡検査中に急性大動脈解離をきたした1例

    齊木 雅史, 西川 晋吾, 吉澤 孝浩, 道津 洋介, 神山 潤二, 園田 智明, 北園 聡, 柳谷 典子, 堀池 篤, 大柳 文義, 西尾 誠人

    気管支学   Vol. 40 ( Suppl. ) page: S333 - S333   2018.5

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

  27. 新型デバイスViziShot2でEBUS-TBNAの診断率は向上するか?

    吉澤 孝浩, 西川 晋吾, 齊木 雅史, 神山 潤二, 園田 智明, 道津 洋介, 内堀 健, 北園 聡, 柳谷 典子, 堀池 篤, 大柳 文義, 西尾 誠人

    気管支学   Vol. 40 ( Suppl. ) page: S198 - S198   2018.5

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

  28. Identification of osimertinib resistance mechanisms using plasma cell-free DNA and tissue biopsy in EGFR-mutated T790M-positive Japanese patients with lung cancer.

    Ryo Ariyasu, Ken Uchibori, Kazuma Kiyotani, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Makoto Nishio, Ryohei Katayama

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 15 )   2018.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2018.36.15_suppl.e21051

    Web of Science

  29. EGFR遺伝子変異陽性非小細胞肺癌に対するPD-1抗体の有効性の検討

    道津 洋介, 堀池 篤, 吉澤 孝浩, 園田 智明, 神山 潤二, 齊木 雅史, 有安 亮, 内堀 健, 西川 晋吾, 北園 聡, 柳谷 典子, 宝来 威, 西尾 誠人, 二宮 浩範, 石川 雄一

    肺癌   Vol. 58 ( 2 ) page: 164 - 164   2018.4

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  30. 【肺癌-最新の治療戦略と失敗しないための秘訣】進行・再発肺癌の最新治療 ALK融合遺伝子陽性非小細胞肺癌の1次治療

    神山 潤二, 堀池 篤, 西尾 誠人

    呼吸器ジャーナル   Vol. 65 ( 4 ) page: 608 - 614   2017.11

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <Point>ALK融合遺伝子は強力ながん遺伝子であり,ALK融合遺伝子陽性非小細胞肺癌(ALK肺癌)において,その増殖や生存はALKに大きく依存している.ALK肺癌に対しては,ALKチロシンキナーゼ阻害薬(ALK-TKI)が著効する.ALK-TKIは,プラチナ併用化学療法と比べ有意に無増悪生存期間(progression free survival;PFS)を延長することが示されており,1次治療から推奨される.複数のALK-TKI(クリゾチニブ,アレクチニブ,セリチニブ)が承認されており,それぞれの薬剤の特徴を知ることが重要である.(著者抄録)

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J06862&link_issn=&doc_id=20171027200011&doc_link_id=10.11477%2Fmf.1437200084&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1437200084&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  31. Multi-probe droplet digital PCR increased the detection efficiency of plasma EGFR exon 19 deletion mutation

    Satoru Kitazono, Kazuko Sakai, Junji Koyama, Ryo Ariyasu, Shingo Nishikawa, Noriko Yanagitani, Atsushi Horiike, Makoto Nishio, Kazuto Nishio

    ANNALS OF ONCOLOGY   Vol. 28   2017.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:OXFORD UNIV PRESS  

    Web of Science

  32. 非小細胞肺癌の薬物療法と生存期間の変遷

    高野 夏希, 有安 亮, 神山 潤二, 園田 智明, 齊木 雅史, 川嶋 庸介, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 大柳 文義, 堀池 篤, 弦間 昭彦, 西尾 誠人

    肺癌   Vol. 57 ( 5 ) page: 424 - 424   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  33. 進行・再発非小細胞肺がんにおけるc-MET発現の検討

    有安 亮, 堀池 篤, 神山 潤二, 齊木 雅史, 園田 智明, 高野 夏希, 川嶋 庸介, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 大柳 文義, 二宮 浩範, 石川 雄一, 西尾 誠人

    肺癌   Vol. 57 ( 5 ) page: 451 - 451   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  34. ニボルマブによる免疫関連肺障害の臨床的検討

    齊木 雅史, 大柳 文義, 有安 亮, 神山 潤二, 園田 智明, 川嶋 庸介, 高野 夏希, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 堀池 篤, 負門 克典, 宝来 威, 西尾 誠人

    肺癌   Vol. 57 ( 5 ) page: 469 - 469   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  35. 免疫チェックポイント阻害剤後の化学療法の毒性

    神山 潤二, 北園 聡, 有安 亮, 齊木 雅史, 園田 智明, 高野 夏希, 川嶋 庸介, 小栗 知世, 西川 晋吾, 柳谷 典子, 堀池 篤, 大柳 文義, 西尾 誠人

    肺癌   Vol. 57 ( 5 ) page: 470 - 470   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  36. 血漿EGFR-T790M陽性例の臨床的特徴

    園田 智明, 柳谷 典子, 有安 亮, 神山 潤二, 齊木 雅史, 川嶋 庸介, 高野 夏希, 小栗 知世, 西川 晋吾, 北園 聡, 堀池 篤, 大柳 文義, 海原 和巳, 西尾 誠人

    肺癌   Vol. 57 ( 5 ) page: 454 - 454   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  37. 【診断と治療のABC[123]呼吸器腫瘍】(第4章)治療 進行期非小細胞肺がんの薬物療法 免疫チェックポイント阻害薬

    神山 潤二, 北園 聡, 西尾 誠人

    最新医学   Vol. 別冊 ( 呼吸器腫瘍 ) page: 179 - 187   2017.6

     More details

    Language:Japanese   Publisher:(株)最新医学社  

    2012年に,進行固形がんに対するニボルマブの忍容性と効果,特に,長期に奏功を維持する症例もあることが報告され,以後,さまざまな免疫チェックポイント阻害薬が開発されている.免疫チェックポイント阻害薬は,非小細胞肺がん患者の生存期間を延長することが示され,肺がん診療に大きな変革をもたらした.一方で従来の化学療法とは異なる毒性対策の必要性や,医療費負担の問題もあり,実地診療では薬剤の適正使用を心がける必要がある.(著者抄録)

  38. The reasons why re-biopsies were not performed after failure with EGFR-TKI.

    Tomoyo Oguri, Atsushi Horiike, Ryo Ariyasu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Natsuki Takano, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e20540

    Web of Science

  39. Clinical and radiological features of advanced RET-rearranged lung cancer

    Masafumi Saiki, Fumiyoshi Ohyanagi, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Yosuke Kawashima, Natsuki Takano, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Hironori Ninomiya, Kengo Takeuchi, Yuichi Ishikawa, Katsunori Oikado, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e23104

    Web of Science

  40. Correlation of low CT attenuation and necrotic features of tumor in contrast-enhanced CT with nivolumab response

    Ryo Ariyasu, Atsushi Horiike, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Natsuki Takano, Yosuke Kawashima, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Katsunori Oikado, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e23105

    Web of Science

  41. Detection of EGFR mutations in NSCLC patients in clinical practice: Comparison between cobas and Scorpion ARMS method

    Natsuki Takano, Satoru Kitazono, Ryo Ariyasu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Yosuke Kawashima, Tomoyo Oguri, Shingo Nishikawa, Noriko Yanagitani, Fumiyoshi Ohyanagi, Atsushi Horiike, Takeshi Horai, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e23101

    Web of Science

  42. Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo).

    Yosuke Kawashima, Shingo Nishikawa, Rya Ariyasu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Natsuki Takano, Tomoyo Oguri, Satoru Kitazono, Yuichi Tambo, Noriko Yanagitani, Fumiyoshi Ohyanagi, Atsushi Horiike, Takeshi Horai, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e20583

    Web of Science

  43. Preexistence of CT findings with usual interstitial pneumonia (UIP) pattern correlates to radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients receiving chemoradiotherapy (CRT).

    Junji Koyama, Satoru Kitazono, Ryo Ariyasu, Masafumi Saiki, Tomoaki Sonoda, Yosuke Kawashima, Natsuki Takano, Tomoyo Oguri, Shingo Nishikawa, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Katsunori Oikado, Takuyo Kozuka, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e20063

    Web of Science

  44. The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice.

    Tomoaki Sonoda, Noriko Yanagitani, Masafumi Saiki, Ryo Ariyasu, Junji Koyama, Natsuki Takano, Yosuke Kawashima, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Fumiyoshi Ohyanagi, Atsushi Horiike, Makoto Nishio

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35   2017.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    DOI: 10.1200/JCO.2017.35.15_suppl.e20575

    Web of Science

  45. 既存肺の間質性陰影と化学放射線療法(CRT)による肺障害の関係

    神山 潤二, 北園 聡, 有安 亮, 齊木 雅史, 園田 智明, 川嶋 庸介, 高野 夏希, 小栗 知世, 西川 晋吾, 柳谷 典子, 堀池 篤, 大柳 文義, 負門 克典, 小塚 拓洋, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 651 - 651   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  46. ニボルマブ投与症例におけるアーカイブ検体を用いた免疫組織化学法の検討

    北園 聡, 榊原 里江, 稲村 健太郎, 神山 潤二, 高野 夏希, 有安 亮, 齊木 雅史, 園田 智明, 川嶋 庸介, 小栗 知世, 西川 晋吾, 柳谷 典子, 堀池 篤, 大柳 文義, 二宮 浩範, 宝来 威, 石川 雄一, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 530 - 530   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  47. 一般診療におけるEGFR遺伝子変異とニボルマブの抗腫瘍効果の関連

    西川 晋吾, 北園 聡, 神山 潤二, 有安 亮, 園田 智明, 齊木 雅史, 川嶋 庸介, 小栗 知世, 高野 夏希, 柳谷 典子, 大柳 文義, 堀池 篤, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 562 - 562   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  48. 中枢神経系転移を有する非小細胞肺癌に対するNivolumabの有効性の検討

    堀池 篤, 有安 亮, 小栗 知世, 神山 潤二, 齊木 雅史, 園田 智明, 高野 夏希, 川嶋 庸介, 西川 晋吾, 北園 聡, 柳谷 典子, 大柳 文義, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 567 - 567   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  49. 初回EGFR-TKI耐性後に再生検ができなかった症例についての検討

    小栗 知世, 堀池 篤, 園田 智明, 齊木 雅史, 神山 潤二, 有安 亮, 高野 夏希, 川嶋 庸介, 西川 晋吾, 北園 聡, 柳谷 典子, 大柳 文義, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 661 - 661   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  50. 当科で経験したRET融合遺伝子陽性肺癌(RET肺癌)の検討

    齊木 雅史, 大柳 文義, 有安 亮, 神山 潤二, 園田 智明, 川嶋 庸介, 高野 夏希, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 堀池 篤, 負門 克典, 二宮 浩範, 竹内 賢吾, 石川 雄一, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 553 - 553   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  51. 当院でのEGFR遺伝子検査におけるCobas法とScorpion ARMS法の比較

    高野 夏希, 北園 聡, 神山 潤二, 有安 亮, 園田 智明, 齊木 雅史, 川嶋 庸介, 小栗 知世, 西川 晋吾, 柳谷 典子, 大柳 文義, 堀池 篤, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 659 - 659   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  52. T790M陽性EGFR陽性非小細胞肺がんに対する実地臨床でのOsimertinibの効果と毒性

    園田 智明, 柳谷 典子, 有安 亮, 神山 潤二, 齊木 雅史, 川嶋 庸介, 高野 夏希, 小栗 知世, 西川 晋吾, 北園 聡, 堀池 篤, 大柳 文義, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 662 - 662   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  53. ALK融合遺伝子陽性肺癌におけるALK阻害剤耐性機序の検討

    柳谷 典子, 片山 量平, 園田 智明, 高野 夏希, 川嶋 庸介, 有安 亮, 神山 潤二, 齊木 雅史, 小栗 知世, 西川 晋吾, 北園 聡, 大柳 文義, 堀池 篤, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 549 - 549   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  54. Nivolumab奏効例の造影CT画像に特徴はあるか?

    有安 亮, 堀池 篤, 神山 潤二, 齊木 雅史, 園田 智明, 高野 夏希, 川嶋 庸介, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 大柳 文義, 負門 克典, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 568 - 568   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  55. Nivolumab投与症例における効果予測因子の検討

    川嶋 庸介, 大柳 文義, 神山 潤二, 有安 亮, 園田 智明, 齊木 雅史, 高野 夏希, 小栗 知世, 西川 晋吾, 北園 聡, 柳谷 典子, 堀池 篤, 宝来 威, 西尾 誠人

    肺癌   Vol. 56 ( 6 ) page: 565 - 565   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  56. 当院で施行した超音波気管支鏡ガイド下針生検(EBUS-TBNA)例についての検討

    横井 英人, 久賀 孝郎, 灰本 千夏, 和田 裕紀子, 神山 潤二, 伊藤 浩, 町田 和彦, 松尾 正樹

    気管支学   Vol. 38 ( Suppl. ) page: S259 - S259   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本呼吸器内視鏡学会  

  57. EGFR遺伝子変異陽性肺癌患者におけるEGFR-TKI投与後のre-biopsyに関する検討

    神山 潤二, 松尾 正樹, 町田 和彦, 伊藤 浩, 横井 英人, 和田 裕紀子, 久賀 孝郎, 灰本 千夏

    肺癌   Vol. 55 ( 5 ) page: 485 - 485   2015.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  58. CYP3A4誘導剤リファブチンによるゲフィチニブ血中濃度の変動を測定した肺癌と肺MAC症の合併例

    伊藤 浩, 中根 茂喜, 平松 久典, 神山 潤二, 中村 さや, 町田 和彦, 松尾 正樹

    肺癌   Vol. 54 ( 5 ) page: 643 - 643   2014.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  59. P1-1-7 当院におけるEBUS-GS導入による肺癌の診断率(EBUS-GS)所見(EBUS-GS,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    中村 さや, 松尾 正樹, 町田 和彦, 伊藤 浩, 神山 潤二

    気管支学   Vol. 36 ( Special ) page: S232 - S232   2014

     More details

    Language:Japanese   Publisher:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.36.special_s232_4

    CiNii Research

  60. P2-7-2 職業関連疾患の多い当科における軟性気管支鏡を用いた局所麻酔下胸腔鏡検査の検討(腹腔鏡-1,一般演題ポスター,第36回日本呼吸器内視鏡学会学術集会)

    伊藤 浩, 神山 潤二, 中村 さや, 高村 智恵, 矢口 大三, 松下 明弘, 町田 和彦, 松尾 正樹

    気管支学   Vol. 35 ( Special ) page: S254 - S254   2013

     More details

    Language:Japanese   Publisher:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.35.special_s254_2

▼display all

Industrial property rights 2

  1. 情報処理装置、情報処理方法、および、コンピュータプログラム

    神山潤二, 古川大記, 森瀬昌宏, 横田秀夫

     More details

    Application no:PCT/JP2023/008495  Date applied:2023.3

    Announcement no:WO2023/176576  Date announced:2023.9

  2. 情報処理装置、情報処理方法、および、コンピュータプログラム

    神山潤二, 古川大記, 森瀬昌宏, 横田秀夫

     More details

    Application no:特願2022-043291  Date applied:2022.3